Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon

7 trials 4 recruiting Academic / non-commercial

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

4 Recruiting

1 Completed trials

2 Countries active

8 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase I

Phase I (FiH)

Phase III: 3 Phase II: 1 Phase IV: 1 Phase I: 1 Phase I (FiH): 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Autism spectrum disorder 1

Top IMPs

ARBACLOFEN 1 CILASTATIN SODIUM, IMIPENEM MONOHYDRATE 1 DAPAGLIFLOZIN 1 SODIUM THIOSULFATE 1 THYTREG 1

All trials

7 total

efficacy and safety of the use of regulatory T cells in immune hyperactivation in patients with COVID-19 and/or acute respiratory distress s… Pending

2024-519799-25-00 Phase I (FiH) 1 country
Effects of sodium-glucose cotransporter 2 inhibition on the mechanisms of heart failure with preserved ejection fraction Pending

2025-520969-51-00 Phase IV 1 country DAPAGLIFLOZIN
A Follow-Up Shiftability Study of Arbaclofen with an Open-Label Extension for the study of Biomarkers for Treatment for Social Function in C… Recruiting

2023-508407-20-00 Phase III 2 countries ARBACLOFEN
Phase I / II clinical trial, randomized, exploratory and prospective to evaluate the safety and efficacy of the transfusion of autologous TR… Recruiting

2024-519845-30-00 Phase I 1 country THYTREG
COLCHICINE IN SECONDARY PREVENTION OF VASCULAR EVENTS AND RENAL PROGRESSION IN PATIENTS WITH MODERATE CHRONIC RENAL DISEASE Recruiting

2023-505868-11-00 Phase III 1 country
To compare cilastatin vs thiosulfatein renal protection in patients undergoing debulking surgery with intraoperative hyperthermic intraperit… Recruiting

2024-518854-18-00 Phase II 1 country CILASTATIN SODIUM, IMIPENEM MONOHYDRATE; SODIUM THIOSULFATE
CMV preemptive therapy in high-risk immunocompetent major heart surgery patients. A multicenter, double blind, randomized, clinical trial (G… Ended

2022-501429-19-00 Phase III 1 country

Showing 1–7 of 7 trials

← All sponsors A–Z